Search Close


Scancell and Isu Chemical Announce Collaboration and Licensing Agreement for Scancell's Antibody

04th February 2002

Scancell and Isu Chemical Announce Collaboration and Licensing Agreement for Scancell's Antibody Cancer Drug SC100 in the Far East

Nottingham, UK – 4th February 2002 – Scancell Ltd today announced a collaboration and licensing agreement with Korean based ISU Chemical Co Ltd on its DeImmunised anti-Epidermal Growth Factor receptor (EGFr) antibody SC100. Under the terms of the agreement ISU Chemical will develop and market SC100 in Korea and other territories in the Far East. ISU will pay for the development and commercialisation of SC100 in the territory. Scancell will receive royalties on the sale of SC100 and access to all data generated by ISU for use in the development of SC100 in Europe and the US.

In addition ISU Chemical will invest $1 million in Scancell.

"Scancell is very pleased to have signed this deal with ISU on SC100" said Dr Richard Goodfellow, Commercial Director at Scancell. " Korea is rapidly establishing itself as a major player in biotechnology and ISU is at the forefront of this research. The deal with ISU will accelerate the development of SC100 and bring forward the time at which the product can enter clinical trials."

"ISU is delighted to have strengthened its antibody therapeutic development portfolio by signing this deal with Scancell", said Dr Chang Hoon Choi, Managing Director of ISU's Biotech Unit. "We believe that Scancell's expertise in the discovery of novel antigens and development of early-stage immunotherapeutics, and in particular monoclonal antibodies, will be strongly complementary to ISU's strengths in antibody production technology. We expect this initial agreement to be just the start of a successful long-term partnership between the two companies."

Scancell's expertise lies in the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. SC100 is a unique epidermal growth factor receptor (EGFr) blocking antibody which has been developed for the treatment of any cancer in which the EGFr is upregulated, including lung, colorectal, breast and head and neck cancer. SC100 has been DeImmunised to ensure minimal immunogenicity in patients. Scancell has also identified a large number of novel antigens as potential targets for drug development. Monoclonal antibodies recognising these targets directly induce tumour cell apoptosis and synergise with chemotherapy, thereby reducing toxicity and increasing therapeutic efficacy. Scancell has also developed ImmunoBodies as a platform technology to overcome the present limitations of cancer vaccines. Scancell has previously announced an alliance with Genmab A/S to develop and commercialise human antibody therapeutics against Scancell's novel targets. For more information about Scancell visit

ISU Chemical is a Korean petrochemical company manufacturing a wide range of chemicals, from detergent based to synthetic pharmaceutical intermediates. Since April 2000, ISU has actively sought new business and R&D opportunities in the areas of human therapeutic antibody development and novel drug target discovery through strategic partnerships with innovative biotechnology companies and research organisations throughout the world. ISU's current development portfolio includes a humanized therapeutic monoclonal antibody to an undisclosed target molecule and a recombinant human protein for adjuvant use during chemotherapy. ISU is also undertaking research on novel drug targets for cancer and chronic diseases using antibody proteomics and functional genomics tools, both at its headquarters in Seoul, Korea and at its US biotechnology R&D Centre in Rockville, MD, USA.

Webcasts, Interviews and Media Coverage

Scancell receives European patent protection for immunotherapy platform

The patent protects a new class of cancer vaccines rolling off the Moditope platform

Wed, 23 May 2018 05:28:00

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates.

A placing and subscription at 12 pence a share will account for £6mln of the total.

The company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded.

Wed, 18 Apr 2018 12:18:00

Scancell unveils funding plans for exciting pipeline of next-generation cancer drugs

In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline

Wed, 18 Apr 2018 13:15:00